• bitcoinBitcoin(BTC)$60,852.005.23%
  • ethereumEthereum(ETH)$1,707.674.23%
  • tetherTether(USDT)$1.000.00%
  • binancecoinBNB(BNB)$551.895.22%
  • usd-coinUSDC(USDC)$1.000.00%
  • rippleXRP(XRP)$0.934.02%
  • solanaSolana(SOL)$70.693.81%
  • tronTRON(TRX)$0.3053930.79%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.073.36%
  • HyperliquidHyperliquid(HYPE)$62.445.99%
  • zcashZcash(ZEC)$797.746.63%
  • moneroMonero(XMR)$486.233.71%
  • dogecoinDogecoin(DOGE)$0.0554984.51%
  • leo-tokenLEO Token(LEO)$9.160.36%
  • whitebitWhiteBIT Coin(WBT)$58.244.08%
  • chainlinkChainlink(LINK)$8.835.28%
  • USDSUSDS(USDS)$1.00-0.01%
  • cardanoCardano(ADA)$0.1457644.71%
  • Ethena USDeEthena USDe(USDE)$1.000.03%
  • stellarStellar(XLM)$0.1296444.01%
  • daiDai(DAI)$1.000.02%
  • bitcoin-cashBitcoin Cash(BCH)$199.274.79%
  • nearNEAR Protocol(NEAR)$3.008.93%
  • litecoinLitecoin(LTC)$39.692.71%
  • avalanche-2Avalanche(AVAX)$6.694.98%
  • CantonCanton(CC)$0.0737890.39%
  • Ripple USDRipple USD(RLUSD)$1.000.00%
  • uniswapUniswap(UNI)$4.737.06%
  • tether-goldTether Gold(XAUT)$3,546.850.80%
  • USD1USD1(USD1)$1.000.04%
  • the-open-networkGram (prev. Toncoin)(GRAM)$0.973.74%
  • suiSui(SUI)$0.666.61%
  • Global DollarGlobal Dollar(USDG)$1.000.01%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.12%
  • RainRain(RAIN)$0.003296-8.69%
  • paypal-usdPayPal USD(PYUSD)$1.00-0.01%
  • hedera-hashgraphHedera(HBAR)$0.0515793.52%
  • BittensorBittensor(TAO)$190.887.25%
  • crypto-com-chainCronos(CRO)$0.0413253.62%
  • shiba-inuShiba Inu(SHIB)$0.0000043.51%
  • quant-networkQuant(QNT)$141.976.97%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.120.00%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • MemeCoreMemeCore(M)$0.77-1.14%
  • Falcon USDFalcon USD(USDF)$1.000.00%
  • okbOKB(OKB)$80.174.31%
  • United StablesUnited Stables(U)$1.000.05%
  • pax-goldPAX Gold(PAXG)$3,549.860.79%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • aaveAave(AAVE)$97.800.02%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Lexeo Therapeutics, Inc. (LXEO) Update for LX2006 for the Treatment of Friedreich Ataxia

October 7, 2025
in Market & News
Reading Time: 4 mins read
A A
Lexeo Therapeutics, Inc. (LXEO) Update for LX2006 for the Treatment of Friedreich Ataxia
ShareShareShareShareShare

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Regulatory Update and Interim Phase 1/2 Data Update for LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Call Transcript

YOU MAY ALSO LIKE

Munich RE: A High-Quality Reinsurer Trading Near Fair Value Following Q3 Earnings

Voyager 1 hit one light day but isn't sending home any data right now – Mashable

Company Participants

Louis Tamayo – CFO & Principal Accounting Officer
R. Townsend – CEO & Director
Sandi Tai – Chief Development Officer
Eric Adler – Chief Medical Officer & Head of Research

Conference Call Participants

Tessa Romero – JPMorgan Chase & Co, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Lili Nsongo – Leerink Partners LLC, Research Division
Leland Gershell – Oppenheimer & Co. Inc., Research Division
Mitchell Kapoor – H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good morning, and welcome to the Lexeo Therapeutics webcast presentation on LX2006 for the treatment of Friedreich’s ataxia cardiomyopathy. As a reminder, this call is being recorded today, October 7, 2025.

I would now like to turn the conference over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead.

Louis Tamayo
CFO & Principal Accounting Officer

Earlier today, we released the regulatory update on our discussions to date with the FDA regarding a potential accelerated approval pathway for LX2006 for the treatment of Friedreich’s ataxia cardiomyopathy alongside new interim clinical data from 2 ongoing Phase I/II clinical studies. The press release outlining these updates is available on our website lexeotx.com, and an 8-K was filed with the SEC this morning.

Joining us on today’s call will be Nolan Townsend, Chief Executive Officer; and Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics; Dr. Eric Adler, Chief Medical Officer and Head of Research; and Dr. Manny Otero, Chief Technical Officer, will also be available for Q&A following the call.

Before we begin, I would like to remind you that this call will contain forward-looking statements regarding Lexeo’s future expectations, plans and prospects which constitute forward-looking statements

Credit: Source link

ShareTweetSendSharePin

Related Posts

Munich RE: A High-Quality Reinsurer Trading Near Fair Value Following Q3 Earnings
Market & News

Munich RE: A High-Quality Reinsurer Trading Near Fair Value Following Q3 Earnings

November 22, 2026
Voyager 1 hit one light day but isn't sending home any data right now – Mashable
Market & News

Voyager 1 hit one light day but isn't sending home any data right now – Mashable

November 22, 2026
Week Ahead: Will Dollar’s Resilience In Face Of Falling Stocks And Rates Be Challenged?
Market & News

Week Ahead: Will Dollar’s Resilience In Face Of Falling Stocks And Rates Be Challenged?

November 22, 2026
Athlete swims Strait of Hormuz to raise awareness of Iran war's toll on wildlife – CBS News
Market & News

Athlete swims Strait of Hormuz to raise awareness of Iran war's toll on wildlife – CBS News

November 22, 2026
Next Post
The best Prime Day kitchen deals include up to 50 percent off our favorite Instant Pots, blenders and more

The best Prime Day kitchen deals include up to 50 percent off our favorite Instant Pots, blenders and more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
GTA 6 cost a whopping B to make — here is how it compares to the biggest blockbusters made

GTA 6 cost a whopping $1B to make — here is how it compares to the biggest blockbusters made

November 19, 2026
Man jumps into school bus after driver has medical issue

Man jumps into school bus after driver has medical issue

November 18, 2026
U.S. and Cuban diplomats erupt in shouting match at United Nations

U.S. and Cuban diplomats erupt in shouting match at United Nations

November 15, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!